ArticleDiscover oncology2025
Predictive factors of pathologic good response after neoadjuvant chemoradiotherapy for rectal cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor patients with T3/T4N0, T(any)N+, or locally unresectable rectal cancer, the treatment approach involves preoperative chemoradiation (CRT) followed by radical surgical resection. Our objective was to identify the predictive factors associated with favorable pathologic response in these individuals.
methodsWe analyzed data from patients diagnosed with primary rectal cancer who underwent preoperative chemoradiation (CRT) followed by radical surgery at Changhua Christian Hospital. Information regarding patient demographics, clinical and pathological characteristics, laboratory data collected at baseline and during CRT, as well as perioperative details, was extracted from medical records. These patients were categorized into good-responder and poor-responder groups. We employed Kaplan-Meier curve analysis to evaluate overall survival (OS) and disease-free survival (DFS), and logistic regression to assess the variables related to treatment response.
resultsOverall, 98 patients were enrolled. A strong pathological response to preoperative CRT correlated with improved OS and DFS among patients with locally advanced rectal cancer. The introduction of simultaneous integrated boost (SIB) in long-course radiotherapy (RT) enhanced the pathological response while maintaining manageable acute toxicity.
conclusionsImplementing SIB in long-course RT enhances treatment response while maintaining acceptable acute toxicity. Further studies are required to identify additional predictive factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.